AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Claims 1-55 (canceled).

56. (Currently amended) A recombinant, live, attenuated virus of the Paramyxoviridae family comprising a baculovirus GP64 ~~nonparamyxoviral~~ envelope glycoprotein capable of mediating entry of said recombinant virus into a mammalian cell; wherein said recombinant, live, attenuated virus maintains infective stability when stored at above about 0°C for at least 3.5 days.

57. (Canceled)

58. (Currently amended) The recombinant, live, attenuated virus of claim 56, wherein the baculovirus GP64 nonparamyxoviral envelope glycoprotein comprises [[~~(1)~~]] an ectodomain and a transmembrane domain of the baculovirus GP64 glycoprotein and a C-terminal sequence of a respiratory syncytial virus fusion protein F.

59.-60. (Canceled)

61. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the recombinant, live, attenuated virus of claim 56, wherein said pharmaceutical composition has been stored at above about 0°C for at least 3.5 days.

62.-64. (Canceled)

65. (Currently amended) A pharmaceutical composition comprising the recombinant, live, attenuated virus of claim 61, wherein the composition has been stored ~~under storage conditions~~ at above about 0°C for at least 3.5 days, wherein infectivity of said recombinant, live, attenuated virus at the end of said at least 3.5 days is at least 60% of that at the beginning of said at least 3.5 days, and wherein ~~said storage conditions are such that~~ the average infectivity of wild-type human respiratory syncytial virus A2 strain, when stored at above about 0°C for at least 3.5 days is reduced by more than 40% ~~after said at least 3.5 days under said storage conditions~~.

66.-69. (Canceled)

70. (Currently amended) The recombinant, live, attenuated virus of claim 56, wherein said recombinant, live, attenuated virus further comprises or encodes an immunogenic epitope of a mammalian pathogen.

71.-75. (Canceled)

76. (Currently amended) The recombinant, live, attenuated virus of claim 56, wherein said recombinant, live, attenuated virus comprises a recombinant respiratory syncytial virus fusion protein F which includes a heterologous cytoplasmic tail.

77.-81. (Canceled)

82. (Currently amended) An enveloped recombinant, live, attenuated vertebrate virus comprising a heterologous envelope protein baculovirus GP64, wherein said envelope protein is capable of mediating entry of the recombinant virus into a mammalian cell, wherein the recombinant virus has been stored ~~under storage conditions~~ for at least 3.5 days, wherein infectivity of the recombinant virus at the end of said at least 3.5 days is at least 60% of that at the beginning of said at least 3.5 days, and wherein ~~said storage conditions are such that~~ the average infectivity of a wild-type virus of the same species as the recombinant virus, when stored the same as the recombinant virus for said at least 3.5 days, is reduced by more than 40% ~~after said at least 3.5 days under said storage conditions~~.

83. (Currently amended) The recombinant, live, attenuated virus of claim 82, wherein said virus has been stored ~~storage conditions include maintaining storage temperature or temperatures~~ at above 0°C ~~cumulatively~~ for said at least 3.5 days.

84.-105. (Canceled)

106. (Currently amended) A recombinant, live, attenuated respiratory syncytial virus (RSV) comprising a baculovirus GP64 ~~nonparamyxoviral~~ envelope glycoprotein capable of mediating

entry of said recombinant RSV into a mammalian cell; wherein said envelope protein comprises an ectodomain of a baculovirus envelope GP64 protein; [[~~and~~]] wherein said recombinant RSV lacks endogenous RSV [[~~SH~~]] small hydrophobic protein; and wherein said recombinant RSV maintains infectivity after storage at temperature or temperatures at above 0°C cumulatively for at least 3.5 days.